Personalized prediction for ulcerative colitis treatment response
Part of Digestive system clinical trials.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ulcerative colitis (based on symptoms, scope findings, and biopsy results).
- You are scheduled to start one of these treatments: vedolizumab, ustekinumab, or tofacitinib.
- You (and your family history) are Korean ethnicity.
- Your condition is classified as ulcerative colitis (not “inflammatory bowel disease unclassified”).
- You have not already had surgery to remove the colon because of ulcerative colitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
This study tests whether measuring drug levels in the blood can help doctors find the best dose of vedolizumab (Entyvio) or ustekinumab (Stelara) for people with ulcerative colitis or Crohn's disease. It aims to improve control of these conditions while keeping treatment safe.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
This study tries to better predict how an ulcerative colitis flare will progress by using a mix of your medical information. If you are eligible, your flare details may help researchers build tools that guide future care.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.